Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV. (Q46599509)

23 December 2017

title

Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV. (English)

1 reference

23 December 2017

1 reference

4

Susan H Eshleman

1 reference

23 December 2017

Ann C Collier

1

object named as

Ann C Collier

1 reference

23 December 2017

Angela Kashuba

5

object named as

Angela Kashuba

1 reference

23 December 2017

author name string

Camlin Tierney

2

1 reference

23 December 2017

Gerald F Downey

3

1 reference

23 December 2017

Karin Klingman

6

1 reference

23 December 2017

Emanuel N Vergis

7

1 reference

23 December 2017

Gary E Pakes

8

1 reference

23 December 2017

James F Rooney

9

1 reference

23 December 2017

Alex Rinehart

10

1 reference

23 December 2017

John W Mellors

11

1 reference

23 December 2017

AIDS Clinical Trials Group Protocol A5143 Team

12

1 reference

23 December 2017

publication date

1 March 2008

1 reference

23 December 2017

published in

HIV Clinical Trials

1 reference

23 December 2017

volume

9

1 reference

23 December 2017

issue

2

1 reference

23 December 2017

page(s)

91-102

1 reference

23 December 2017

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

cites work

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-91

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-91

Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-91

Virological rebound after suppression on highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-91

Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-91

Clinical utility of HIV-1 genotyping and expert advice: the Havana trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-91

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-91

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-91

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-91

Pharmacologic perspectives for once-daily antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-91

Principles and practice of HIV-protease inhibitor pharmacoenhancement

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-91

Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-91

Clinical impact of double protease inhibitor boosting with lopinavir/ritonavir and amprenavir as part of salvage antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-91

The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-91

A prospective, controlled study assessing the effect of lopinavir on amprenavir concentrations boosted by ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-91

Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-91

Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-91

Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-91

SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-91

The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-91

A randomized study investigating the efficacy and safety of amprenavir in combination with low-dose ritonavir in protease inhibitor-experienced HIV-infected adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-91

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-91

Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-91

Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-91

Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-91

Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-91

New patterns of HIV-1 resistance during HAART

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-91

Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-91

Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-91

Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-91

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-91

21 January 2018

Identifiers

DOI

10.1310/HCT0902-91

1 reference

23 December 2017

1 reference

23 December 2017